GD2靶向CAR-T细胞治疗神经母细胞瘤患者的长期结局
一项1期临床试验于2004至2009年入组神经母细胞瘤患儿,接受表达GD2靶向第一代CAR的EBV特异性T淋巴细胞和CD3活化T细胞治疗。中位随访至18年,11例活动期患者中3例完全缓解、2例持续缓解;8例无病证据患者中5例末次随访无病。长期生存者转基因持续存在显著更高。
要点
- 11例输注时活动期患者中3例达完全缓解,其中2例持续缓解(1例8年失访,1例超过18年)。
- 8例输注时无病证据患者中5例末次随访(输注后10至15年)无病。
- 随访期间检出间歇性低水平转基因,长期生存者转基因持续存在显著更高。
核心结论
- 尽管使用因缺乏共刺激结构域而不再采用的第一代载体,复发/难治性神经母细胞瘤患者接受GD2 CAR-T细胞治疗后仍获得长期疾病控制,包括1例复发疾病缓解超过18年。
研究设计与样本
- 1期临床试验,2004至2009年开放入组,入组神经母细胞瘤患儿,接受EBV特异性T淋巴细胞和CD3活化T细胞(各自表达靶向GD2的第一代CAR)治疗,CAR嵌入条形码序列以追踪输注群体。
主要发现
- 11例输注时有活动性疾病患者中3例达完全缓解,2例持续缓解:1例持续8年至失访,1例超过18年。
- 8例CAR-T给药时无疾病证据患者中5例末次随访(输注后10至15年)无病。
- 随访期间检出间歇性低水平转基因,长期生存者中转基因持续存在显著更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In a phase 1 clinical trial open to accrual from 2004 to 2009, we treated children with neuroblastoma with Epstein-Barr virus (EBV)-specific T lymphocytes and CD3-activated T cells-each expressing chimeric antigen receptors (CARs) targeting GD2 but without an embedded co-stimulatory sequence (first-generation CARs). These CARs incorporated barcoded sequences to track each infused population. We previously reported outcomes up to 5 years and now report long-term outcomes up to 18 years. Of 11 patients with active disease at infusion, three achieved a complete response that was sustained in two patients, one for 8 years until lost to follow-up and one for more than 18 years. Of eight patients with no evidence of disease at the time of CAR-T administration, five are disease free at their last follow-up between 10 years and 15 years after infusion. Intermittent low levels of transgene were detected during the follow-up period with significantly greater persistence in those who were long-term survivors. Despite using first-generation vectors that are no longer employed because of the lack of co-stimulatory domains, patients with relapsed/refractory neuroblastoma achieved long-term disease control after receiving GD2 CAR-T cell therapy, including one patient now in remission of relapsed disease for more than 18 years.ClinicalTrials.gov identifier: NCT00085930 .
引用
- Li CH, Sharma S, Heczey AA, et al. Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma. Nat Med. 2025. PMID: 39962287. doi:10.1038/s41591-025-03513-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。